Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 7/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 6/20 | 0.38 |
| ▸ | GRIA3 | P42263 | 6/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 6/20 | 0.38 |
| ▸ | ALPI | P09923 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | XIAP | P98170 | 1/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.34 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.34 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.34 |
| ▸ | GRIK4 | Q16099 | 2/20 | 0.34 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Histidine SCHEMBL6426902 | 1.00 | SLC7A5 (0.40) | SLC7A5CYP3A4CYP1A2GRIA2GRIA1 | |
| Histidine SCHEMBL28805947 | 1.00 | SLC7A5 (0.40) | SLC7A5CYP3A4CYP1A2GRIA2GRIA1 | |
| Histidine SCHEMBL6426901 | 1.00 | SLC7A5 (0.40) | SLC7A5CYP3A4CYP1A2GRIA2GRIA1 | |
| Histidine SCHEMBL27597223 | 0.97 | SLC7A5 (0.38) | SLC7A5CYP3A4CYP1A2GRIA2GRIA1 | |
| Histidine SCHEMBL6724968 | 0.97 | SLC7A5 (0.38) | SLC7A5CYP3A4CYP1A2GRIA2GRIA1 | |
| Histidine SCHEMBL6947397 | 0.95 | SLC7A5 (0.37) | SLC7A5CYP3A4CYP1A2GRIA2GRIA1 | |
| Histidine SCHEMBL27504981 | 0.95 | SLC7A5 (0.37) | SLC7A5CYP3A4CYP1A2GRIA2GRIA1 | |
| Histidine SCHEMBL1061772 | 0.91 | SLC7A5 (0.43) | SLC7A5CYP3A4CYP1A2GRIA2GRIA1 | |
| Histidine SCHEMBL1061774 | 0.91 | SLC7A5 (0.43) | SLC7A5CYP3A4CYP1A2GRIA2GRIA1 | |
| Histidine SCHEMBL1537307 | 0.91 | SLC7A5 (0.43) | SLC7A5CYP3A4CYP1A2GRIA2GRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108586615-B | Modified IgG4 bispecific antibodies of sequence symmetry | UCB生物制药有限责任公司 | 2022-03-08 | — | — | CN | claimed |
| CN-105859876-B | Improved IgG4 class antibodies | UCB医药有限公司 | 2021-04-02 | — | — | CN | claimed |
| EP-3670531-A1 | ASYMMETRIC, MODIFIED IGG4 BISPECIFIC ANTIBODIES | UCB Biopharma SRL (BE) | 2020-06-24 | — | — | EP | claimed |
| US-20200157204-A1 | Antibodies of the Class IGG4 | UCB Biopharma SRL (BE) | 2020-05-21 | — | — | US | claimed |
| EP-3156416-B1 | SEQUENCE SYMMETRIC MODIFIED IGG4 BISPECIFIC ANTIBODIES | UCB BIOPHARMA SPRL (BE) | 2019-11-20 | — | — | EP | claimed |
| CN-108586615-A | The IgG4 bispecific antibodies of the modification of sequence symmetry | UCB医药有限公司 | 2018-09-28 | — | — | CN | claimed |
| CN-104321341-B | Modified IgG4 bispecific antibodies of sequence symmetry | UCB医药有限公司 | 2018-05-22 | — | — | CN | claimed |
| US-9902768-B2 | Sequence asymmetric modified IgG4 bispecific antibodies | UCB BIOPHARMA SPRL (BE) | 2018-02-27 | — | — | US | claimed |
| EP-2606063-B1 | IMPROVED ANTIBODIES OF THE CLASS IGG4 | UCB BIOPHARMA SPRL (BE) | 2017-05-17 | — | — | EP | claimed |
| EP-3156416-A1 | SEQUENCE SYMMETRIC MODIFIED IGG4 BISPECIFIC ANTIBODIES | UCB Biopharma SPRL (BE) | 2017-04-19 | — | — | EP | claimed |
| CN-105859876-A | Improved antibodies of the class IgG4 | UCB医药有限公司 | 2016-08-17 | — | — | CN | claimed |
| EP-2817332-B1 | SEQUENCE SYMMETRIC MODIFIED IGG4 BISPECIFIC ANTIBODIES | UCB BIOPHARMA SPRL (BE) | 2016-07-20 | — | — | EP | claimed |
| CN-103097410-B | Improved IgG4 class antibodies | UCB PHARMA S.A. (BE) | 2016-06-01 | — | — | CN | claimed |
| EP-2817333-A1 | SEQUENCE SYMMETRIC MODIFIED IGG4 BISPECIFIC ANTIBODIES | UCB Pharma, S.A. (BE) | 2014-12-31 | — | — | EP | claimed |
| EP-2817332-A1 | SEQUENCE SYMMETRIC MODIFIED IGG4 BISPECIFIC ANTIBODIES | UCB Pharma S.A. (BE) | 2014-12-31 | — | — | EP | claimed |
| US-20130323236-A1 | Antibodies of the Class IGG4 | UCB PHARMA S.A. (BE) | 2013-12-05 | — | — | US | claimed |
| WO-2013124450-A1 | SEQUENCE SYMMETRIC MODIFIED IGG4 BISPECIFIC ANTIBODIES | UCB PHARMA S.A. (BE) | 2013-08-29 | — | — | WO | claimed |
| WO-2013124451-A1 | SEQUENCE SYMMETRIC MODIFIED IGG4 BISPECIFIC ANTIBODIES | UCB PHARMA S.A. (BE) | 2013-08-29 | — | — | WO | claimed |
| CN-108586615-B | Modified IgG4 bispecific antibodies of sequence symmetry | UCB生物制药有限责任公司 | 2022-03-08 | — | — | CN | disclosed |
| WO-2012022982-A2 | IMPROVED ANTIBODIES OF THE CLASS IGG4 | UCB PHARMA S.A. (BE) | 2012-02-23 | — | — | WO | disclosed |